Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA

To be competitive in plaque psoriasis, Pfizer’s Xeljanz may need its higher dose – but it will have to convince FDA to approve a dose it rejected due to safety concerns in rheumatoid arthritis.